Overview

Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)

Status:
Completed

Trial end date:
2009-02-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to collect information on unexpected adverse reactions (ADRs), how often ADRs occur, and factors that can affect the safety and effectiveness of Claritin (loratadine) when used in children. Patients will be observed while they are taking Claritin, and ADRs and symptom scores will be recorded. At the end of treatment, improvement in symptoms will be recorded. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Loratadine

Criteria

Inclusion Criteria:

- Pediatric patients aged 3 to 15 years who are treated with Claritin for any of the
following reasons: allergic rhinitis, urticaria, itching due to skin disease (eczema,
dermatitis, or pruritus cutaneous)

Exclusion Criteria:

- (None)